Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.

被引：0
|
作者：
Strati, Paolo
Leslie, Lori Ann
Shiraz, Parveen
Budde, L. Elizabeth
Oluwole, Olalekan O.
Ulrickson, Matthew
Ramakrishnan, Aravind
Sun, Jennifer
Shen, Rhine
Kanska, Justyna
McCroskery, Peter
Dong, Jinghui
Schupp, Marco Andreas
Xu, Hairong
Patel, Krish
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
[2] John Theurer Canc Ctr, Hackensack, NJ USA
[3] Stanford Univ, Stanford, CA USA
[4] City Hope Natl Med Ctr, Duarte, CA USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Banner MD Anderson Canc Ctr, Gilbert, AZ USA
[7] Texas Transplant Physician Grp, Austin, TX USA
[8] Gilead Co, Kite, Santa Monica, CA USA
[9] Swedish Canc Inst, Seattle, WA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7567
引用
收藏
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) AND TISAGENLECLEUCEL (TISA-CEL) IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL) IN CANADA
    Ball, G.
    Kuruvilla, J.
    Boodoo, C.
    Jain, M. D.
    VALUE IN HEALTH, 2021, 24 : S39 - S39
  • [22] Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).
    Jacobson, Caron A.
    Locke, Frederick Lundry
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobadi, Armin
    Miklos, David Bernard
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew Alexander
    Herr, Megan
    Hill, Brian T.
    Ganguly, Siddhartha
    Dong, Hua
    Nikiforow, Sarah
    Xie, Jing
    Xu, Hairong
    Hooper, Michele
    Kawashima, Jun
    Pasquini, Marcelo C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
    Neelapu, Sattva S.
    Jacobson, Caron A.
    Oluwole, Olalekan O.
    Munoz, Javier
    Deol, Abhinav
    Miklos, David B.
    Bartlett, Nancy L.
    Braunschweig, Ira
    Jiang, Yizhou
    Kim, Jenny J.
    Zheng, Lianging
    Rossi, John M.
    Locke, Frederick L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
  • [24] Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction
    Locke, Frederick L.
    Jacobson, Caron
    Ma, Long
    Dong, Hua
    Hu, Zhen-Huan
    Siddiqi, Tanya
    Ahmed, Sairah
    Ghobad, Armin
    Miklos, David B.
    Lin, Yi
    Perales, Miguel-Angel
    Lunning, Matthew A.
    Herr, Megan M.
    Hill, Brian T.
    Ganguly, Siddhartha
    Mirza, Abu-Sayeef
    Nikiforow, Sarah
    Xu, Hairong
    Pasquini, Marcelo C.
    BLOOD, 2021, 138
  • [25] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
    Khurana, Arushi
    Bailey, Megumi
    Iqbal, Madiha
    Bansal, Radhika
    Lee, Catherine J.
    Hunter, Bradley
    Lunning, Matthew A.
    Jaglowski, Samantha
    Jain, Michael D.
    Dahiya, Saurabh
    Bachanova, Veronika
    Farooq, Umar
    Ahmed, Sairah
    Hill, Brian T.
    Munoz, Javier L.
    Patel, Krish
    Oluwole, Olalekan O.
    Lin, Yi
    BLOOD, 2022, 140 : 4657 - 4660
  • [26] Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 12 - 14
  • [27] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Herrera, Alex F.
    Westin, Jason R.
    Lee, Jennifer
    Rossi, John M.
    Zheng, Lianqing
    Avanzi, Mauro P.
    Roberts, Zachary J.
    Sun, Jennifer
    BLOOD, 2018, 132
  • [28] End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
    Jacobson, Caron A.
    Locke, Frederick L.
    Miklos, David B.
    Herrera, Alex F.
    Westin, Jason R.
    Lee, Jennifer
    Rossi, John M.
    Sun, Jennifer
    Zheng, Lianqing
    Avanzi, Mauro P.
    Roberts, Zachary J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [29] Primary Analysis of ZUMA7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) versus StandardofCare (SOC) Therapy in Patients (Pts) with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Ghobadi, Armin
    Locke, Frederick L.
    Miklos, David B.
    Jacobson, Caron A.
    Perales, Miguel-Angel
    Kersten, Marie Jose
    Oluwole, Olalekan O.
    Rapoport, Aaron P.
    McGuirk, Joseph P.
    Pagel, John M.
    Munoz, Javier
    Farooq, Umar
    van Meerten, Tom
    Reagan, Patrick M.
    Sureda, Anna
    Flinn, Ian W.
    Vandenberghe, Peter
    Song, Kevin W.
    Dickinson, Michael
    Minnema, Monique C.
    Riedell, Peter A.
    Leslie, Lori A.
    Chaganti, Sridhar
    Yang, Yin
    Filosto, Simone
    Schupp, Marco
    To, Christina
    Cheng, Paul
    Gordon, Leo I.
    Westin, Jason R.
    MOLECULAR THERAPY, 2022, 30 (04) : 519 - 519
  • [30] ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).
    Neelapu, Sattva Swarup
    Chavez, Julio C.
    Lin, Yi
    Munoz, Javier
    Ujjani, Chaitra Shankar
    Riedell, Peter
    De Vos, Sven
    Oluwole, Olalekan O.
    Kekre, Natasha
    Yang, Yin
    Goyal, Lovely
    Backhouse, Kate
    Milletti, Francesca
    Kawashima, Jun
    Herrera, Alex Francisco
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345